Serum In­sti­tute of In­dia in talks to se­cure a fill-fin­ish deal for the Ox­ford malar­ia vac­cine in Ghana

The vac­cine man­u­fac­tur­er Serum In­sti­tute of In­dia is look­ing to es­tab­lish fill-fin­ish op­er­a­tions in Ghana for the new­ly ap­proved Ox­ford R21 malar­ia vac­cine.

The Serum In­sti­tute is hold­ing talks with Ghana­ian com­pa­ny DEK Vac­cines to see how the vac­cine could be fill-fin­ished and pro­duced in Ghana, said William Am­po­fo, the sec­re­tary of the pres­i­den­tial com­mit­tee on vac­cine man­u­fac­tur­ing and de­vel­op­ment, in a press con­fer­ence host­ed by the WHO Africa. How­ev­er, Am­po­fo did not give any de­tails about the deal so far. End­points News reached out to Serum In­sti­tute and DEK for more in­for­ma­tion but did not re­ceive a re­sponse by press time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER